Narrative review of the emerging role of molecular biomarkers in guiding the definitive management of unresectable non-small cell lung cancer

per Singhi, Eric K., Gay, Carl M.
Publicat a Transl Lung Cancer Res (2020)

Diverse functions for the semaphorin receptor PlexinD1 in development and disease

per Gay, Carl M., Zygmunt, Tomasz, Torres-Vázquez, Jesús
Publicat 2010

Giving AXL the axe: targeting AXL in human malignancy

per Gay, Carl M, Balaji, Kavitha, Byers, Lauren Averett
Publicat a Br J Cancer (2017)

Targeting DNA damage repair in small cell lung cancer and the biomarker landscape

per Sen, Triparna, Gay, Carl M., Byers, Lauren Averett
Publicat a Transl Lung Cancer Res (2018)

Beyond chemotherapy - emerging biomarkers and therapies as SCLC enters the immune checkpoint era

per Della Corte, Carminia M., Gay, Carl M., Byers, Lauren A.
Publicat a Cancer (2019)

GIPC proteins negatively modulate Plexind1 signaling during vascular development

per Carretero-Ortega, Jorge, Chhangawala, Zinal, Hunt, Shane, Narvaez, Carlos, Menéndez-González, Javier, Gay, Carl M, Zygmunt, Tomasz, Li, Xiaochun, Torres-Vázquez, Jesús
Publicat a eLife (2019)

Differential Sensitivity Analysis for Resistant Malignancies (DISARM) identifies common candidate therapies across platinum-resistant cancers

per Gay, Carl M., Tong, Pan, Cardnell, Robert J., Sen, Triparna, Su, Xiao, Ma, Jun, Bara, Rasha O., Johnson, Faye M., Wakefield, Chris, Heymach, John V., Wang, Jing, Byers, Lauren A.
Publicat a Clin Cancer Res (2018)

A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma

per Gay, Carl M., Zhou, Yanhong, Lee, J. Jack, Tang, Xi Ming, Lu, Wei, Wistuba, Ignacio I., Ferrarotto, Renata, Gibbons, Don L., Glisson, Bonnie S., Kies, Merrill S., Simon, George R., Heymach, John V., Tsao, Anne S.
Publicat a Oncologist (2020)

Effects of Surgery on Survival of Early-Stage Patients With SCLC: Propensity Score Analysis and Nomogram Construction in SEER Database

per Wang, Yuyan, Zheng, Qiwen, Jia, Bo, An, Tongtong, Zhao, Jun, Wu, Meina, Zhuo, Minglei, Li, Jianjie, Zhong, Jia, Chen, Hanxiao, Yang, Xue, Chi, Yujia, Dong, Zhi, Sepesi, Boris, Zhang, Jianjun, Gay, Carl M., Wang, Ziping
Publicat a Front Oncol (2020)

Combination treatment of the oral CHK1 inhibitor, SRA737 and low dose gemcitabine, enhances the effect of PD-L1 blockade by modulating the immune microenvironment in small cell lun...

per Sen, Triparna, Della Corte, Carminia M., Milutinovic, Snezana, Cardnell, Robert J, Diao, Lixia, Ramkumar, Kavya, Gay, Carl M., Stewart, C Allison, Fan, Youhong, Shen, Li, Hansen, Ryan J., Strouse, Bryan, Hedrick, Michael P., Hassig, Christian A., Heymach, John V., Wang, Jing, Byers, Lauren A
Publicat a J Thorac Oncol (2019)

AXL inhibition induces DNA damage and replication stress in non-small cell lung cancer cells and promotes sensitivity to ATR inhibitors

per Ramkumar, Kavya, Stewart, C. Allison, Cargill, Kasey R., Corte, Carminia M. Della, Wang, Qi, Shen, Li, Diao, Lixia, Cardnell, Robert J., Peng, David H., Rodriguez, B. Leticia, Fan, You-Hong, Heymach, John V., Wang, Jing, Gay, Carl M., Gibbons, Don L., Byers, Lauren A.
Publicat a Mol Cancer Res (2020)

Toxicity and Survival after Intensity-Modulated Proton Therapy (IMPT) versus Passive Scattering Proton Therapy (PSPT) for Non-Small Cell Lung Cancer

per Gjyshi, Olsi, Xu, Ting, Elhammali, Adnan, Boyce-Fappiano, David, Chun, Stephen G, Gandhi, Saumil, Lee, Percy, Chen, Aileen B, Lin, Steven H, Chang, Joe Y, Tsao, Anne, Gay, Carl M, Zhu, X Ronald, Zhang, Xiadong, Heymach, John V, Fossella, Frank V, Lu, Charles, Nguyen, Quynh-Nhu, Liao, Zhongxing
Publicat a J Thorac Oncol (2020)

Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer

per Stewart, C. Allison, Tong, Pan, Cardnell, Robert J., Sen, Triparna, Li, Lerong, Gay, Carl M., Masrorpour, Fatemah, Fan, You, Bara, Rasha O., Feng, Ying, Ru, Yuanbin, Fujimoto, Junya, Kundu, Samrat T., Post, Leonard E., Yu, Karen, Shen, Yuqiao, Glisson, Bonnie S., Wistuba, Ignacio, Heymach, John V., Gibbons, Don L., Wang, Jing, Byers, Lauren Averett
Publicat a Oncotarget (2017)

Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer

per Stewart, C. Allison, Gay, Carl M., Xi, Yuanxin, Sivajothi, Santhosh, Sivakamasundari, V., Fujimoto, Junya, Bolisetty, Mohan, Hartsfield, Patrice M., Balasubramaniyan, Veerakumar, Chalishazar, Milind D., Moran, Cesar, Kalhor, Neda, Stewart, John, Tran, Hai, Swisher, Stephen G., Roth, Jack A., Zhang, Jianjun, de Groot, John, Glisson, Bonnie, Oliver, Trudy G., Heymach, John V., Wistuba, Ignacio, Robson, Paul, Wang, Jing, Byers, Lauren Averett
Publicat a Nat Cancer (2020)

STING pathway expression identifies non-small cell lung cancers with an immune-responsive phenotype

per Corte, Carminia M. Della, Sen, Triparna, Gay, Carl M., Ramkumar, Kavya, Diao, Lixia, Cardnell, Robert J., Rodriguez, B. Leticia, Stewart, C. Allison, Papadimitrakopoulou, Vassiliki A., Gibson, Laura, Fradette, Jared J., Wang, Qi, Fan, Youhong, Peng, David H., Negrao, Marcelo V., Witsuba, Ignacio I., Fujimoto, Junya, Soto, Luisa M. Solis, Behrens, Carmen, Skoulidis, Ferdinandos, Heymach, John V., Wang, Jing, Gibbons, Don L., Byers, Lauren A.
Publicat a J Thorac Oncol (2020)

Lung cancer models reveal SARS-CoV-2-induced EMT contributes to COVID-19 pathophysiology

per Stewart, C. Allison, Gay, Carl M., Ramkumar, Kavya, Cargill, Kasey R., Cardnell, Robert J., Nilsson, Monique B., Heeke, Simon, Park, Elizabeth M., Kundu, Samrat T., Diao, Lixia, Wang, Qi, Shen, Li, Xi, Yuanxin, Zhang, Bingnan, Della Corte, Carminia Maria, Fan, Youhong, Kundu, Kiran, Gao, Boning, Avila, Kimberley, Pickering, Curtis R., Johnson, Faye M., Zhang, Jianjun, Kadara, Humam, Minna, John D., Gibbons, Don L., Wang, Jing, Heymach, John V., Byers, Lauren Averett
Publicat a bioRxiv (2021)

Lung Cancer Models Reveal Severe Acute Respiratory Syndrome Coronavirus 2–Induced Epithelial-to-Mesenchymal Transition Contributes to Coronavirus Disease 2019 Pathophysiology

per Stewart, C. Allison, Gay, Carl M., Ramkumar, Kavya, Cargill, Kasey R., Cardnell, Robert J., Nilsson, Monique B., Heeke, Simon, Park, Elizabeth M., Kundu, Samrat T., Diao, Lixia, Wang, Qi, Shen, Li, Xi, Yuanxin, Zhang, Bingnan, Della Corte, Carminia Maria, Fan, Youhong, Kundu, Kiran, Gao, Boning, Avila, Kimberley, Pickering, Curtis R., Johnson, Faye M., Zhang, Jianjun, Kadara, Humam, Minna, John D., Gibbons, Don L., Wang, Jing, Heymach, John V., Byers, Lauren Averett
Publicat a J Thorac Oncol (2021)

Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities

per Gay, Carl M., Allison Stewart, C., Park, Elizabeth M., Diao, Lixia, Groves, Sarah M., Heeke, Simon, Nabet, Barzin Y., Fujimoto, Junya, Solis, Luisa M., Lu, Wei, Xi, Yuanxin, Cardnell, Robert J., Wang, Qi, Fabbri, Giulia, Cargill, Kasey R., Vokes, Natalie I., Ramkumar, Kavya, Zhang, Bingnan, Della Corte, Carminia M., Robson, Paul, Swisher, Stephen G., Roth, Jack A., Glisson, Bonnie S., Shames, David S., Wistuba, Ignacio I., Wang, Jing, Quaranta, Vito, Minna, John, Heymach, John V., Byers, Lauren Averett
Publicat a Cancer Cell (2021)

CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-L1 blockade

per Chen, Limo, Diao, Lixia, Yang, Yongbin, Yi, Xiaohui, Leticia Rodriguez, B., Li, Yanli, Villalobos, Pamela A., Cascone, Tina, Liu, Xi, Tan, Lin, Lorenzi, Philip L., Huang, Anfei, Zhao, Qiang, Peng, Di, Fradette, Jared J., Peng, David H., Ungewiss, Christin, Roybal, Jonathon, Tong, Pan, Oba, Junna, Skoulidis, Ferdinandos, Peng, Weiyi, Carter, Brett W., Gay, Carl M., Fan, Youhong, Class, Caleb A., Zhu, Jingfen, Rodriguez-Canales, Jaime, Kawakami, Masanori, Averett Byers, Lauren, Woodman, Scott E., Papadimitrakopoulou, Vassiliki A., Dmitrovsky, Ethan, Wang, Jing, Ullrich, Stephen E., Wistuba, Ignacio I., Heymach, John V., Xiao-Feng Qin, F., Gibbons, Don L.
Publicat a Cancer Discov (2018)

Integrative Molecular Characterization of Malignant Pleural Mesothelioma

per Hmeljak, Julija, Sanchez-Vega, Francisco, Hoadley, Katherine A., Shih, Juliann, Stewart, Chip, Heiman, David, Tarpey, Patrick, Danilova, Ludmila, Drill, Esther, Gibb, Ewan A., Bowlby, Reanne, Kanchi, Rupa, Osmanbeyoglu, Hatice U., Sekido, Yoshitaka, Takeshita, Jumpei, Newton, Yulia, Graim, Kiley, Gupta, Manaswi, Gay, Carl M., Diao, Lixia, Gibbs, David L., Thorsson, Vesteinn, Iype, Lisa, Kantheti, Havish, Severson, David T., Ravegnini, Gloria, Desmeules, Patrice, Jungbluth, Achim A., Travis, William D., Dacic, Sanja, Chirieac, Lucian R., Galateau-Sallé, Françoise, Fujimoto, Junya, Husain, Aliya N., Silveira, Henrique C., Rusch, Valerie W., Rintoul, Robert C., Pass, Harvey, Kindler, Hedy, Zauderer, Marjorie G., Kwiatkowski, David J., Bueno, Raphael, Tsao, Anne S., Creaney, Jenette, Lichtenberg, Tara, Leraas, Kristen, Bowen, Jay, Felau, Ina, Zenklusen, Jean Claude, Akbani, Rehan, Cherniack, Andrew D., Byers, Lauren A., Noble, Michael S., Fletcher, Jonathan A., Robertson, Gordon, Shen, Ronglai, Aburatani, Hiroyuki, Robinson, Bruce W., Campbell, Peter, Ladanyi, Marc
Publicat a Cancer Discov (2018)